Learn about our Share Purchase Plan

A message from the Chairman

 

Dear Fellow Shareholders,

 

It is my pleasure to invite you to participate in the Share Purchase Plan (SPP) for Kazia Therapeutics. Eligible shareholders have the opportunity to purchase up to $15,000 of new shares in the Company, at a price of $0.38, and without incurring costs for brokerage or other transaction fees.

 

As you will be aware, we recently completed a placement to high-quality sector-specialist institutional investors, which represents a powerful endorsement of both the quality of our pipeline and the work that has been done over the past several years to move it forward. Your Board felt it was important that our existing shareholders be offered the same opportunity in recognition of their longstanding support of the Company. To this end, the SPP provides an opportunity to acquire shares on the same terms as the recent placement. I and my fellow directors intend to participate.

 

The next twelve months is a very exciting period for Kazia, with four high-impact data read-outs across our two programs. The funds we have raised in the placement will enable to see through the phase IIa study of GDC-0084 and the phase I study of Cantrixil. We have also been very gratified by the interest and enthusiasm of a number of leading researchers to explore GDC-0084 in other forms of brain cancer, and we recently launched collaborations with St Jude Children’s Research Hospital in a childhood brain cancer and with Dana-Farber Cancer Institute in patients with breast cancer that has spread to the brain.

 

The Board have not set a target for the SPP, because we consider it primarily an opportunity to ensure our existing shareholders are treated equitably. Nevertheless, the proceeds of the SPP will help us to fund additional projects such as those we have launched with St Jude and with Dana-Farber, broadening the commercial opportunity for GDC-0084, generating additional value-driving data, and allowing us to potentially benefit a much greater number of patients.

 

I refer you to the SPP booklet which contains full information. All eligible shareholders will be mailed personalised application forms. On behalf of the Board, I encourage you to carefully consider the opportunity to strengthen your investment in the Company. We continue to be grateful for your support.

 

Yours faithfully,

Iain Ross
Chairman of the Board

 

About the SPP
 
Key dates

We have included the key dates below, but please refer to the official documentation which is available via the ASX Announcements section of this website for dates and conditions.

 

How do you participate in the SPP?

If you were a holder of KZA securities on the record date of 7.00pm (AEST) Wednesday, 17 October 2018, you are invited to subscribe for up to $15,000 worth of new, fully paid, ordinary shares in Kazia (SPP Shares), without incurring brokerage or other transaction costs.

 

The SPP opens on Tuesday, 23 October 2018 and is expected to close at 5.00pm (AEST) on Friday, 16 November 2018. SPP Shares are expected to commence trading on ASX on Monday, 26 November 2018.

 

To apply for SPP Shares, you must either:

  • Complete and return the personalised Application Form, together with payment via cheque; or

  • Make a payment directly via BPAY (you do not need to return an Application Form under this option).

  • Log onto www.investorcentre.com/au using your Holder ID and postcode or username and password. Once logged in, select 'Statements and Documents' and click to view your form via 'SPP Applications' dated 23 October 2018.

 

Haven’t received your paperwork?

If you haven’t received your paperwork by 29 October, please contact our share registry, Computershare, who can arrange to get paperwork to you. 

 

Questions about how to participate

A number of questions are covered in the SPP documentation, which you can view here

 

If you have any questions in relation to how to participate in the SPP after reading the Booklet, please contact Kazia's Share Registry Computershare (within Australia 1300 855 080 and For Overseas callers +61 3 9415 4000).

 

Would you like us to contact you?

If you have specific questions about Kazia’s programs or this capital raising and would like to speak with one of our people, please contact our Company Secretary, Kate Hill via +61 448 417 880 or info@kaziatherapeutics.com.

 

SITE BY SPATIAL DESIGN